TBZF Inhibitors
Chemical inhibitors of TBZF include a range of compounds that target key signaling pathways involved in its activation and function. Bisindolylmaleimide I, Gö 6983, and GF109203X are all inhibitors of Protein Kinase C (PKC). PKC plays a pivotal role in the phosphorylation and subsequent activation of transcription factors, including TBZF. By inhibiting PKC, these compounds prevent the phosphorylation-dependent changes required for the optimal activity of TBZF, thereby reducing its ability to carry out its role in transcription regulation. Similarly, LY294002 and Wortmannin exert their inhibitory effect on TBZF by targeting the PI3K/AKT pathway. This pathway is integral to a variety of cellular functions, including transcription regulation. The inhibition of PI3K leads to a decrease in downstream signaling that is crucial for maintaining the functional state of TBZF, effectively diminishing its activity within the cell.
Moreover, PD98059, U0126, and SL327 specifically target the MEK1/2 enzymes, thus blocking the ERK/MAPK pathway. This pathway is involved in the regulation of transcription factors and their activity. The inhibition of MEK1/2 means that the necessary ERK/MAPK signaling for TBZF activity is hindered, which translates into reduced functional capabilities of TBZF. In addition, SB203580 and SB202190, as inhibitors of p38 MAP Kinase, contribute to the reduction of TBZF activity by preventing the phosphorylation events that are vital for the activation of transcription factors influenced by cellular stress responses. SP600125, on the other hand, inhibits the c-Jun N-terminal kinase (JNK), thereby preventing the required post-translational modifications of TBZF that occur through phosphorylation, which are essential for its activity. Lastly, Rapamycin inhibits mTOR, a component of the PI3K/AKT pathway, which further contributes to the reduction of TBZF activity by impeding signaling pathways that support TBZF's transcriptional regulatory functions.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I inhibits Protein Kinase C (PKC), which is necessary for the activation of transcription factors. Inhibition of PKC can lead to the reduced activity of TBZF by preventing its phosphorylation and subsequent activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, and since PI3K signaling is crucial for various cellular functions including transcription, its inhibition can diminish the activity of TBZF by reducing the signaling that contributes to its functional state. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK1, which in turn blocks the ERK/MAPK pathway. TBZF's activity can be reduced due to the blockade of this pathway, which is involved in the regulation of various transcription factors and their activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP Kinase, a kinase involved in cellular stress responses. By inhibiting p38, the phosphorylation states and therefore the functional activities of various transcription factors including TBZF can be reduced. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which modulates transcription factors through phosphorylation. Blocking JNK can lead to decreased functional activity of TBZF by preventing its necessary post-translational modifications. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K like LY294002, and as such, it can decrease TBZF activity by inhibiting downstream signaling required for TBZF's optimal function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a broad-spectrum PKC inhibitor. By inhibiting PKC activity, it can reduce the phosphorylation and therefore the activation of TBZF, thus functionally inhibiting it. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of the ERK/MAPK pathway. This can lead to reduced TBZF function since this pathway is implicated in the regulation of transcription factors' activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is another p38 MAP Kinase inhibitor, and by inhibiting p38, it can suppress the activity of TBZF by affecting the phosphorylation and activation of related transcription factors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT pathway and is involved in regulating protein synthesis and transcription. Inhibition of mTOR can reduce the functional activity of TBZF by impeding the pathway's support for its activity. | ||||||